Swiss firm Clariant to set up healthcare packaging plant in Tamil Nadu

The new plant, to be built with an investment of CHF 10 million (about Rs 64 crore), will produce moisture-control products such as desiccant, adsorbent polymers, etc

Clariant's desiccant packets for pharma packaging
Clariant's desiccant packets for pharma packaging
Rakesh Rao Mumbai
Last Updated : Dec 01 2015 | 12:14 PM IST
Swiss specialty chemicals major Clariant will invest about CHF 10 million (about Rs 64 crore) in a healthcare packaging manufacturing plant at Cuddalore in Tamil Nadu. The plant will manufacture Clariant’s moisture control products to support the growing pharmaceutical packaging market in India.
 
“This new manufacturing facility is in alignment with our overall growth strategy in the country. The new facility will enable us to enhance our medical specialties business and offer end-to-end solutions to our existing as well as potential customers. Clariant in India is accelerating change and continues to fulfil our commitments to all our stakeholders, as the Indian market stays at the core of Clariant’s global focus,” commented Dr Deepak Parikh, region president - India, Clariant.
 
Clariant healthcare packaging, a member of masterbatches business unit, manufactures a full range of controlled atmosphere packaging solutions including pharmaceutical desiccants, equilibrium sorbents, adsorbent polymers, oxygen scavengers and pharmaceutical closures and containers. The new plant in Cuddalore will initially produce desiccant canisters and packets, which are inserted into pharmaceutical packaging to control moisture and protect the stability of the medicine during shelf life. The desiccant production facility will be compliant with all relevant current good manufacturing practice (cGMP) and US FDA standards.
 
Ketan Premani, head of Clariant healthcare packaging sales in India, said, “India is the largest provider of generic drugs globally making it a key market for Clariant’s desiccant products. We want to ensure that we serve our customers here as directly and efficiently as possible. When the plant is complete, they will now have the ability to procure Clariant’s global-standard products directly produced in India.”
 
The new healthcare packaging plant in Cuddalore - together with its plant in Changshu, China and the recent acquisition of healthcare packaging specialist VitaPac, located in Dongguan, China - positions Clariant to play a major role in the expanding healthcare sector across Asia.
 
Creating another base for desiccant canister and packet production also supports Clariant’s rigorous business-continuity goals. “More and more global pharmaceutical companies are instituting business-continuity plans, or BCP, to deal with possible market disruptions, both natural and man-made. This new plant will support our ability to provide the same products from multiple plants in Asia and around the world,” explained Matthias Brommer, vice president and head of Clariant healthcare packaging.
 
The new plant will primarily serve globally active generic and branded pharmaceutical companies operating in India, as well as the domestic Indian pharmaceutical market. According to Markets and Markets, a major global market-research firm, India’s pharmaceutical packaging market is projected to grow at a compounded annual growth rate (CAGR) of 10.2 percent from 2015 to 2020. India Ratings & Research, another research company with six offices across India, recently reported that Indian drug makers accounted for 40 percent of US generic drug imports. It forecasts a 20 percent CAGR for the overall pharmaceutical market through 2020.
 
Marco Cenisio, senior vice president and general manager of masterbatches business unit, Clariant, said, “The significant investment in Cuddalore of our new healthcare packaging plant further strengthens our commitment to capture the growth opportunities that exist in emerging markets and specifically in the highly attractive market in India. It also highlights the commitment of our business unit to devote a large portion of the capital budget to our Healthcare Packaging business to continue to fund its growth.”
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 01 2015 | 12:11 PM IST

Next Story